Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

(2014) Scott C. Bresler et al.   CANCER CELL

Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

(2014) Christine M Lovly et al.   NATURE MEDICINE

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Receptor Tyrosine Kinases: Legacy of the First Two Decades

(2014) J. Schlessinger   Cold Spring Harbor Perspectives in Biology

Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors

(2014) J. F. Shern et al.   Cancer Discovery

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma

(2013) P Bonvini et al.   BRITISH JOURNAL OF CANCER

Distinct Effects of Ligand-Induced PDGFR  and PDGFR  Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments

(2013) M. Ehnman et al.   CANCER RESEARCH

Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array

(2013) Riki Nishimura et al.   CANCER SCIENCE

Control of ALK (wild type and mutated forms) phosphorylation: Specific role of the phosphatase PTP1B

(2013) M.C. Boutterin et al.   CELLULAR SIGNALLING

LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor

(2013) Jianyong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

Anaplastic lymphoma kinase status in rhabdomyosarcomas

(2013) Akihiko Yoshida et al.   MODERN PATHOLOGY

Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth

(2013) C L Yeung et al.   ONCOGENE

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

(2013) Samuel Q. Li et al.   PLoS One

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

(2013) M. J. Niederst et al.   Science Signaling

Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks

(2013) J. P. Wagner et al.   Science Signaling

Complexity of Receptor Tyrosine Kinase Signal Processing

(2013) N. Volinsky et al.   Cold Spring Harbor Perspectives in Biology

Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

(2012) Seiji Yano et al.   CANCER SCIENCE

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

(2012) T. Yamada et al.   CLINICAL CANCER RESEARCH

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

(2012) H. Y. Zou et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

(2012) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment

(2012) Pierre Mazot et al.   PLoS One

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

(2011) C. M. Lovly et al.   CANCER RESEARCH

Targeting Anaplastic Lymphoma Kinase in Lung Cancer

(2011) A. T. Shaw et al.   CLINICAL CANCER RESEARCH

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications

(2011) J. Carlijn van Gaal et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

(2011) P Mazot et al.   ONCOGENE

Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model

(2010) F. Huang et al.   CANCER RESEARCH

Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer

(2010) L. Cao et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Spatial control of EGF receptor activation by reversible dimerization on living cells

(2010) Inhee Chung et al.   NATURE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

(2009) P. Sabbatini et al.   MOLECULAR CANCER THERAPEUTICS

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma

(2008) F. Diomedi-Camassei et al.   CLINICAL CANCER RESEARCH

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE